Orchestra BioMed Holdings Inc. - Asset Resilience Ratio
Orchestra BioMed Holdings Inc. (OBIO) has an Asset Resilience Ratio of 65.60% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Orchestra BioMed Holdings Inc.'s Asset Resilience Ratio has changed over time. Check Orchestra BioMed Holdings Inc. strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Orchestra BioMed Holdings Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Orchestra BioMed Holdings Inc. (OBIO) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $66.03 Million | 65.6% |
| Total Liquid Assets | $66.03 Million | 65.60% |
Asset Resilience Insights
- Very High Liquidity: Orchestra BioMed Holdings Inc. maintains exceptional liquid asset reserves at 65.60% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Orchestra BioMed Holdings Inc. Industry Peers by Asset Resilience Ratio
Compare Orchestra BioMed Holdings Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Galapagos NV
F:GXEA |
Biotechnology | 86.45% |
|
Nanobiotix S.A
PA:NANO |
Biotechnology | 53.40% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 34.30% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Orchestra BioMed Holdings Inc. (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Orchestra BioMed Holdings Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 62.53% | $71.82 Million | $114.86 Million | +4.05pp |
| 2024-12-31 | 58.49% | $44.55 Million | $76.17 Million | -1.42pp |
| 2023-12-31 | 59.90% | $57.04 Million | $95.21 Million | -7.06pp |
| 2022-12-31 | 66.97% | $64.00 Million | $95.57 Million | +59.88pp |
| 2021-12-31 | 7.08% | $958.00K | $13.53 Million | -33.47pp |
| 2020-12-31 | 40.55% | $15.45 Million | $38.09 Million | -- |
About Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develop… Read more